Skip to main content
Medical information Clinical review pending

Genetic Testing

MECP2 Gene Central Hypoventilation Syndrome Congenital Genetic Test

This genetic test analyzes the MECP2 gene to help diagnose congenital central hypoventilation syndrome, a condition affecting breathing, particularly during sleep. It uses Next Generation Sequencing (NGS) technology.

General information only: This page is not a diagnosis or personal medical advice. A qualified clinician should decide whether testing is appropriate and interpret results in context.

Review status: No completed medical review is recorded for this page.

Ask a question
Counselor guidance included Confidential handling Kenya-wide coordination

At a glance

Plan your test

Sample
Blood sample (EDTA tube), extracted DNA, or a dried blood spot on an FTA card. Confirm specific requirements with the laboratory before booking.
Results
Approximately 3 to 4 weeks. Confirm with the laboratory before booking.
Preparation
A clinical history of the patient and a genetic counseling session, including a pedigree chart of affected family members, are required before testing.
Test priceKSh 40,000

Payment: M-Pesa and card options can be confirmed during booking.

Insurance & government schemes

Is this test covered for you?

We help you verify whether the MECP2 Gene Central Hypoventilation Syndrome Congenital Genetic Test test can be claimed against your insurer, employer scheme or a Kenyan government health scheme — before you book. Coverage depends on your plan, clinical indication and your provider's rules; final approval always rests with them.

Talk to a claims advisor

Providers & schemes we can help you check

Government & public schemes

SHIF — Social Health Insurance Fund Linda Mama EduAfya NHIF (legacy cards)

Eligibility and benefits follow the current rules of the Social Health Authority (SHA) and applicable government programmes.

Private insurers & employer schemes

Jubilee Health AAR APA Britam CIC Madison Resolution Pioneer Minet Old Mutual GA Life Heritage + other licensed insurers

Names shown for identification only — listing does not imply partnership or guarantee of coverage.

Have these ready when we check

  • Insurer or scheme name & policy / member number
  • A clinician's request / prescription for the test
  • Pre-authorisation letter, if your plan requires one

Free coverage check

Ask us to verify your cover

Send your details and our claims team confirms what documents you need and whether pre-authorisation applies — usually the same working day.

+254

Used only to process your coverage check — see our Privacy Policy. Verification support is free and does not guarantee your provider will pay.

01

Start with fit

Is this the right test for you?

The best test starts with a clear clinical question. These are common reasons a clinician or family may consider this test.

  • ✓Individuals with symptoms suggestive of congenital central hypoventilation syndrome (e.g., breathing difficulties, especially during sleep).
  • ✓Infants or children with unexplained respiratory problems.
  • ✓Individuals with a family history of CCHS or related MECP2 disorders.
  • ✓Confirmation of a suspected CCHS diagnosis.
  • ✓Genetic counseling for families with a history of CCHS.
02

In plain language

What this test helps you understand

This test helps identify mutations in the MECP2 gene associated with congenital central hypoventilation syndrome (CCHS) and related disorders. It aids in confirming a diagnosis, understanding the underlying cause of respiratory issues, and guiding management strategies.
This test examines the MECP2 gene, which is linked to certain neurological conditions, including congenital central hypoventilation syndrome (CCHS). CCHS is a rare disorder where individuals have difficulty breathing, especially during sleep, due to problems with the brain's control over breathing.

This test uses advanced Next Generation Sequencing (NGS) technology to look for specific changes (mutations) in the MECP2 gene. Identifying these mutations can help confirm a diagnosis of CCHS or related disorders.

Understanding the genetic basis of CCHS is important for managing the condition effectively and for providing genetic counseling to families.
03

Medical review status

Clinical review pending

A completed medical review is not recorded for this page. No clinician has endorsed the information shown here. Please discuss testing decisions with a qualified healthcare professional.

Meet the DNA Labs Kenya medical team →
04

A simple process

What happens next?

You do not have to navigate the test alone. We help you move from question to next step.

1

Speak with us

We check the test and answer your questions before collection.

2

Give your sample

Choose home collection or a coordinated hub visit in Kenya. We explain whether this test uses a cheek swab or blood draw.

3

Understand your report

A counselor helps you understand the result and the next steps.

05

Choose your collection

Home collection or a lab visit

We will explain the sample, preparation, and next steps before anything is collected.

Home collection

Choose a coordinated visit at home or another convenient location. Our team confirms the appointment and sample requirements in advance.

Lab or hub visit

Prefer to visit a coordinated location? We can guide you to the right hub and explain what to expect when you arrive.

Ask about locations →
PreparationA clinical history of the patient and a genetic counseling session, including a pedigree chart of affected family members, are required before testing.
SampleBlood sample (EDTA tube), extracted DNA, or a dried blood spot on an FTA card. Confirm specific requirements with the laboratory before booking.
MethodologyNext Generation Sequencing (NGS) is used to analyze the MECP2 gene for mutations.
PrivacyYour sample and report are handled confidentially. Ask the team how your information is stored and shared.
This test specifically analyzes the MECP2 gene. It may not detect mutations in other genes that could cause similar symptoms. Results need to be interpreted in the context of the patient's clinical presentation and family history. Not all MECP2 mutations are fully understood.
06

Read your report

What common result terms mean

PositiveA finding was identified. Your clinician or counselor will explain what it means for your care.
NegativeThe specific finding tested for was not identified. It does not rule out every possible cause.
VUSA variant was found, but current evidence is not enough to classify it. Your counselor can explain follow-up.
07

Questions people ask

Frequently asked questions

CCHS is a rare disorder where the brain doesn't properly control breathing, especially during sleep, leading to breathing difficulties.
Mutations in the MECP2 gene are a known cause of CCHS and related neurological disorders. Testing this gene helps identify the genetic basis of the condition.
A blood sample, extracted DNA, or a dried blood spot on an FTA card can be used. Please confirm the preferred sample type with the lab.
The turnaround time is typically 3 to 4 weeks, but this can vary. Confirm the current turnaround time with the laboratory.
Results will be interpreted by a genetic counselor who will discuss the findings with you and your doctor, explaining the implications and next steps.
08

Collaboration

Open for partnership with hospitals, clinics, doctors & researchers

Whether you are referring patients, building a research programme or supporting students, we work as an extension of your team — with responsive communication and clear scientific standards.

Hospitals & clinics

Referral pathways, coordinated sample logistics and shared reporting that fits your clinical workflow.

Doctors & specialists

LOINC-coded reports, ACMG-based variant classification and a direct scientific line for complex cases.

Research institutions

Sanger sequencing, NGS panels and custom assays — with project design support, batch pricing and agreed turnaround commitments.

Students & academic projects

Discounted laboratory services for college, master's and PhD research projects — including proposal guidance and cost-effective batch testing.

Explore partnerships
09

Trust & transparency

Sources, standards & how this page is maintained

Standards & references

  • ACMG/AMP technical standards for sequence variant interpretation
  • ClinGen curation and gene–disease validity frameworks where applicable
  • LOINC-coded reporting for interoperable results
  • ISO 9001:2015 quality management; ISO 15189 accreditation in progress

Page provenance

  • Last updated: September 27, 2026
  • Medical review: not yet completed
  • Written for patients & clinicians in Kenya; reviewed periodically against current guidance

Medical disclaimer: this page is general information, not a diagnosis or personal medical advice. Testing decisions and result interpretation should be made with a qualified healthcare professional.

Keep exploring

Related tests

View all tests →
Chat on WhatsApp